Many cancers are hormonally driven. Ultimately, a predictive assay combining information from tumor estrogen receptor status, mutational analysis, aromatase levels and estrogen metabolite analysis may prove to have clinical benefit. Estrogen metabolites profiled from tumor tissue may aid in evolving a strategy that targets cancer pathways in solid tumors by enhancing our understanding of estrogens produced locally via aromatase or via ligand dependent signaling. Ultimately, a rational co-inhibition of ER and related receptors may result in greater anti-tumor activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011227-03
Application #
8349414
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2011
Total Cost
$20,378
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code